ChinaBio® Partnering Forum 2017: HitGen aids China drug discovery with DNA library
Wei Chen, head of R&D for Chengdu-based HitGen describes to Scrip’s Brian Yang how the Chinese startup partners with multinationals to speed up new drug development in China, and planned IND filing for its HDAC inhibitor for liver cancer. HitGen burst onto the drug discovery scene one year ago, when the Chengdu firm signed a collaboration agreement with J&J, using their own DNA encoded library to screen new targets with a focus on oncology and metabolism conditions. HitGen will provide chemistry and biological support in screening for small molecular lead compounds. Following the deal, Merck & Co. and Pfizer also inked similar collaboration deals with HitGen. The Chengdu firm meanwhile is also developing its own new drug compounds for ophthalmology, cardiovascular, oncology and autoimmune conditions. One of them, a histone deacetylase (HDACs) inhibitor, is being planned for an investigative new drug (IND) filing for hepatica cell carcinoma in 2017. This interview was recorded at ChinaBio® Partnering Forum organized by EBD Group and ChinaBio® Group in Zhuhai, Guangdong, in May 2017.